-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer.
Suzhou, October 18, 2021/PRNewswire/ - On October 18, 2021, Corning Jereh Biopharmaceuticals (stock code: 9966.
ENREACH-LUNG-01 is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous non-small cell lung cancer for evaluation The safety and effectiveness of KN046 combined chemotherapy at a dose of 5 mg/kg was led by Professor Zhou Caicun from Shanghai Pulmonary Hospital as the main investigator.
Professor Zhou Caicun, Director of the Oncology Department of Shanghai Pulmonary Hospital Affiliated to Tongji University, said: "We are very pleased to participate in Corning Jerry’s ENREACH-LUNG-01 study, which is also the first tumor immune bispecific antibody to be used in stage III of lung cancer patients in China.
Dr.
About KN046
KN046 is a PD-L1/CTLA-4 bispecific antibody independently developed by Corning Jereh.
KN046 has carried out nearly 20 clinical trials of different stages covering more than 10 types of tumors including non-small cell lung cancer, thymic cancer, pancreatic cancer, liver cancer, esophageal squamous cell carcinoma, triple negative breast cancer, etc.
About Corning Jerry
Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs
Corning Jereh Biopharmaceuticals has a discovery, R&D, and manufacturing platform for the entire industry chain in bispecific antibody and protein engineering
The company has a number of technical platforms with independent intellectual property rights such as heterodimers and hybrid antibodies, and large-scale production capabilities that meet the cGMP standards of China, the United States and the European Union, and have passed a complete quality system including multiple audits of the European Union QP.
Source: Corning Jerry
